Clinical Trials and Data Coordination Hub

Chronic Disease Prevention  ·  Long-Term Follow-Up  ·  Women’s Health Trials

Garnet Anderson is a clinical trialist and biostatistician whose leadership in the Women’s Health Initiative (WHI) has shaped national understanding of cancer, cardiovascular disease, and chronic illness in postmenopausal women. Her work bridges population-based research and long-term disease prevention.

Biomarker-Guided Trials  ·  Coordinating Center Leadership  ·  Trial Design Methodology 

Ziding Feng leads statistical and data coordination efforts for national multicenter initiatives focused on early cancer detection, biomarker validation, and risk assessment. He serves as principal investigator of coordinating centers for the NCI Early Detection Research Network (EDRN), the Translational Liver Cancer Consortium (TLC), and others. He is  co-PI for the Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN).  His work ensures scientific rigor, collaboration, and data quality across large, multisite studies in cancer prevention and early diagnosis.

Vaccine Trials  ·  Immune Correlates of Protection  ·  Data Coordination

Youyi Fong directs the Statistical and Data Management Center for the HIV Vaccine Trials Network (HVTN), leading the design, coordination, and analysis of international vaccine efficacy studies. His work advances statistical frameworks for assessing immune correlates of protection and ensuring data quality across complex, multi‑site clinical networks.

Vaccine Efficacy ·  Forrelates of Protection  ·  HIV Prevention Trials

Peter Gilbert develops statistical methods for evaluating vaccine efficacy in large-scale HIV prevention trials, with a focus on correlates of protection and immunologic markers. The Gilbert Group. works closely with global consortia to advance robust inference in infectious disease research. 

Clinical Trial Design  ·  Transplant Outcomes Analysis  ·  Oncology Outcomes

Ted Gooley directs the Clinical Biostatistics Program at Fred Hutch, providing statistical leadership for clinical trials in hematopoietic cell transplantation and cancer treatment. His work supports rigorous trial design, analysis, and interpretation across oncology and transplant studies, ensuring high-quality evidence for long-term patient outcomes. 

Cancer Treatment Trials  ·  Cancer Screening Trials  · DCC Leadership

Katherine A. Guthrie leads the study design, conduct, and analysis of clinical trials in the areas of gastrointestinal cancers and palliative care, many of which are conducted through the NCI-funded SWOG Cancer Research Network. She co-leads the Statistics and Data Management Center for the NCI Cancer Screening Research Network (CSRN), created by NCI to evaluate emerging technologies for cancer screening. Her work supports real-world translation of research into health practice.

Cancer Prevention Trials  ·  Risk Modeling  ·  Data Coordination

Charles Kooperberg plays a key leadership role in the Women’s Health Initiative (WHI) and the Cancer Screening Research Network (CSRN), where he contributes to the design and coordination of large-scale cancer prevention and screening trials. His work integrates risk modeling and clinical data to support population-level interventions and long-term outcomes research.

SWOG Trials  ·  Adaptive Design  ·  Cancer Treatment Outcomes

Michael LeBlanc serves as a lead statistician for SWOG Cancer Research Network, supporting the design and analysis of oncology clinical trials across multiple disease areas. He develops and applies adaptive and group-sequential methods to improve trial efficiency and decision-making.

Vaccine Trials ·  HIV Prevention  ·  Trial Inference

Holly Janes leads the statistical design and analysis for HIV prevention trials, translating immunologic and clinical data into estimates of vaccine efficacy and public health impact. Her work guides large-scale prevention studies with global reach.

Precision Oncology Trials  ·  Risk Stratification  ·  SWOG Leadership

Megan Othus develops innovative statistical methods for oncology clinical trials, including precision medicine and risk-adapted designs. As a key statistical leader for SWOG Cancer Research Network, she advances trial frameworks that support personalized treatment strategies.

Prostate Cancer Trials  ·  SWOG Coordination  ·  Trial Design

Catherine Tangen is a senior statistician for SWOG clinical trials in genitourinary cancers, with leadership spanning trial design, implementation, and analysis. Her work supports multi-site collaborations focused on treatment efficacy and survivorship.

Immunotherapy Trials  ·  Biomarker Discovery  · Statistical Modeling

Mike Wu develops statistical methods for cancer immunotherapy trials, with a focus on biomarkers, patient heterogeneity, and early response. His work bridges trial design and computational modeling to improve cancer treatment strategies. Visit the Wu Group to learn more.

Immunotherapy Trials  ·  CAR-T STudy Design  ·   Sample Size Tools

Qian “Vicky” Wu  is the lead biostatistician for more than 20 CAR-T immunotherapy trials at Fred Hutch and Seattle Children’s. Her work supports all phases of trial design, statistical modeling, and data coordination, with a focus on immune-based therapies and translational endpoints. She also develops widely used tools for sample size estimation, trial simulation, and longitudinal outcome analysis.

Adaptive Trials  ·  Precision Medicine  ·  Cancer Treatment Strategies  ·  Early Detection

Yingqi Zhao develops statistical methods for adaptive treatment strategies and precision oncology, with a focus on individualized clinical decision-making. As MPI of Improving the Design and Analysis of Randomized Trials in Cancer Early Detection (IDeA-CED),  she helps lead the development of evaluation frameworks and trial designs for cancer early detection and screening interventions.

Risk Prediction  ·  Biomarker Evaluation  ·  Early Detection

Yingye Zheng develops statistical methods that strengthen the design, conduct, and analysis of cancer screening and prevention trials. Her research focuses on evaluating biomarkers, improving risk stratification, and advancing analytic approaches for randomized and pragmatic trials, with particular attention to early detection settings. By linking methodological innovation with real-world trial implementation, her work informs evidence-based screening strategies and clinical decision-making. Learn more at the Zheng Group and through her role as MPI of Improving the Design and Analysis of Randomized Trials in Cancer Early Detection (IDeA-CED).